Quick Summary
Suboxone (buprenorphine plus naloxone) and methadone are the two most effective medications for treating opioid use disorder. Both reduce cravings, prevent withdrawal, and dramatically lower overdose risk. They work in different ways, are dispensed differently, and have different advantages. The right choice is individualized to the person.
Key Takeaways
- Methadone is a full opioid agonist; Suboxone is a partial agonist (buprenorphine) with a ceiling effect that limits respiratory depression, plus naloxone to deter injection misuse.
- Methadone tends to show somewhat higher treatment retention; both methadone and buprenorphine substantially reduce the risk of overdose death.
- Methadone is dispensed only through certified opioid treatment programs; Suboxone can be prescribed in office-based settings.
- Both work best with counseling, peer support, and treatment of co-occurring conditions.
- The right choice is individualized and made between a person and a qualified prescriber.
Choosing between Suboxone and methadone is one of the most consequential decisions in opioid use disorder treatment, and one that comes up early. Both medications have strong evidence bases and have helped millions of people. They are not interchangeable. The right fit depends on the person’s history, life circumstances, and clinical situation. The information here draws on the National Institute on Drug Abuse’s MOUD overview and the FDA’s MOUD information page.
How Each Medication Works
Methadone
A long-acting full opioid agonist. It binds to opioid receptors completely, producing steady relief from cravings and withdrawal without the highs and crashes of short-acting opioids. Methadone has been used to treat opioid use disorder for more than 50 years.
Suboxone (Buprenorphine plus Naloxone)
Buprenorphine is a partial opioid agonist with a “ceiling effect” that limits its sedating and respiratory depressant effects. This gives it a wider safety margin than a full agonist like methadone. A wider margin does not make overdose impossible: buprenorphine can still cause life-threatening respiratory depression, especially when combined with benzodiazepines, alcohol, or other sedatives (FDA Suboxone prescribing information). The naloxone in Suboxone is included mainly to discourage misuse by injection: if the film or tablet is dissolved and injected, the naloxone triggers withdrawal, while taken as prescribed under the tongue it has minimal effect. Suboxone is one buprenorphine-and-naloxone product; buprenorphine is also available on its own (a mono-product often used in pregnancy) and in other formulations.
Effectiveness Compared
Both medications substantially reduce the risk of overdose death. In one large observational study of people who survived an overdose in Massachusetts, methadone was associated with about a 59 percent reduction in opioid-related deaths and buprenorphine with about a 38 percent reduction, each compared with receiving no medication (Larochelle et al., 2018). Because each medication was compared with no treatment rather than with the other, these figures should not be read as proof that one medication is better than the other. Broader evidence finds both methadone and buprenorphine roughly halve overdose mortality while a person stays in treatment (Sordo et al., 2017). Methadone does tend to show somewhat higher treatment retention.
How They Are Dispensed
This is one of the biggest practical differences. Methadone for opioid use disorder is dispensed only through federally certified opioid treatment programs (OTPs), commonly called methadone clinics. Historically that meant daily visits with take-home doses earned slowly, but under SAMHSA’s updated federal rules (the 2024 changes to 42 CFR Part 8), take-home dosing is now individualized based on clinical judgment and a person’s circumstances. Suboxone can be prescribed by qualified physicians, nurse practitioners, and physician assistants in office-based settings. After an initial induction period, patients pick it up at a pharmacy like any other prescription.
Side Effects and Safety
Both medications can cause constipation, sweating, sleep changes, and reduced libido. Methadone has higher risk of heart rhythm changes in some patients and carries higher overdose risk if combined with other depressants. Suboxone has a wider safety margin, but that does not mean overdose is impossible: buprenorphine can still cause life-threatening respiratory depression, especially in combination with benzodiazepines, alcohol, or other sedatives. Precipitated withdrawal during induction is also a known issue if a person has used full opioid agonists (including fentanyl) recently, which is why the timing of the first dose is guided by a clinician.
We’re here to make treatment as accessible and affordable as possible — and are in network with many insurance providers. Not sure about your coverage? We can help.
Who Might Do Better on Each
This is a clinical decision, not a self-diagnosis. In general:
- Methadone may be a better fit for people with severe long-standing opioid use disorder, high tolerance, history of multiple unsuccessful treatments, or chronic pain alongside OUD.
- Suboxone may be a better fit for people who prefer office-based treatment, have transportation challenges getting to a clinic daily, or have safety concerns that favor a partial agonist. Buprenorphine works across all severity levels of opioid use disorder, including severe, so severity alone does not decide the choice.
What About Vivitrol (Naltrexone)?
Naltrexone (the extended-release injection is sold as Vivitrol) is a third FDA-approved option that works differently: it is an opioid antagonist that blocks opioid effects rather than activating the receptor. Its main challenge is getting started, because a person must be fully off opioids (about 7 to 10 days) before the first dose. Once successfully started, extended-release naltrexone was about as effective as buprenorphine-naloxone at preventing relapse in the X:BOT trial; the difference showed up mostly at the initiation stage. It is a legitimate option worth discussing, not an afterthought.
Length of Treatment
There is no required end date for either medication. Some people use them for months, others for years, others indefinitely. The decision to taper is individualized and made between a person and their prescriber based on stability, risks, and personal goals.
What Both Have in Common
Both medications work best when combined with counseling, peer recovery support, and treatment for any co-occurring mental health conditions. The medication is one part of the picture. The combination produces the best outcomes.
Talking With a Professional
The right choice depends on details that only an assessment can clarify. The admissions team at Discovery Point Retreat can talk through what an assessment involves and what options exist.
References
- Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137-145. NIH summary.
- Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. Full text.
- Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309-318. Full text.
- US Food and Drug Administration. Suboxone (buprenorphine and naloxone) prescribing information (boxed warning). Accessed June 8, 2026. accessdata.fda.gov.
- Substance Abuse and Mental Health Services Administration. 42 CFR Part 8 final rule: medications for the treatment of opioid use disorder. 2024. Accessed June 8, 2026. samhsa.gov.
- National Institute on Drug Abuse. Medications to treat opioid use disorder. Accessed June 8, 2026. nida.nih.gov.
- US Food and Drug Administration. Information about medications for opioid use disorder (MOUD). Accessed June 8, 2026. fda.gov.
Resources
- 988 Suicide and Crisis Lifeline. Call or text 988, or chat at 988lifeline.org. Free, confidential support 24/7.
- SAMHSA National Helpline. Call 1-800-662-HELP (4357) or visit the SAMHSA National Helpline page for free, confidential referrals to local treatment.
- 911. For any medical emergency, call 911 immediately.
This article is general education and is not medical advice. It does not establish a clinician-patient relationship and is not a substitute for an individual assessment by a qualified mental health or addiction treatment professional.
